Logo

BioTime Subsidiary Inks Stem Cell Distribution Deal

Jun 26, 2008
NEW YORK (GenomeWeb News) – BioTime said yesterday that its Embryome Sciences subsidiary has inked a manufacturing and distribution deal with Lifeline Cell Technology, a subsidiary of International Stem Cell.
 
The partners intend to manufacture cell lines and supplies that scientists will use in stem cell research for regenerative medicine and drug discovery. They said the progenitor cell lines will be produced and distributed jointly using Emryome Sciences’ Embryonics technology, International Stem Cell’s parthenogenetic stem cell lines derived from unfertilized human eggs, and technology and approved hES cell lines licensed from the Wisconsin Alumni Research Foundation.
 
Data from the cell lines will be presented on Embryome Sciences’ future Embryome.com online database, Alameda, Calif.-based BioTime said. International Stem Cell also will contribute manufacturing and quality-control expertise.
 
Financial terms of the alliance were not disclosed.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.